Cognex Corporation reported its fourth-quarter earnings for 2024, revealing an adjusted earnings per share (EPS) of $0.20, surpassing the estimated EPS of $0.16. The company's sales reached $229.684 million, exceeding the expected $220.664 million. In a separate announcement, Dexcom, Inc. also released its fourth-quarter earnings for 2024, showing a revenue increase of 8% year-over-year to $1.114 billion, which slightly beat the estimate of $1.103 billion. However, Dexcom's adjusted EPS of $0.45 fell short of the $0.50 estimate. The company reaffirmed its fiscal year 2025 guidance, projecting revenue of $4.60 billion, reflecting a 14% growth. Additionally, Dexcom reported a GAAP EPS of $0.38 for the fourth quarter.